Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 4-amino-n-(1-(3-cyclohexen-1-ylmethyl)-4-piperidyl)-2-ethoxy-5-nitrobenzamide
2. Blaston
3. Cidine
4. Cinitapride Tartrate
1. 66564-14-5
2. Paxapride
3. Cidine
4. Cinitapride [inn]
5. Cinitapride Hydrogen Tartrate
6. 4-amino-n-[1-(cyclohex-3-en-1-ylmethyl)piperidin-4-yl]-2-ethoxy-5-nitrobenzamide
7. R8i97i2l24
8. 66564-14-5 (free Base)
9. Cinitapride (inn)
10. 4-amino-n-(1-(3-cyclohexen-1-ylmethyl)-4-piperidyl)-2-ethoxy-5-nitrobenzamide
11. Cinitaprida
12. Cinitapridum
13. Cinitapridum [inn-latin]
14. Cinitaprida [inn-spanish]
15. Cidin
16. Unii-r8i97i2l24
17. Paxapride (tn)
18. Cinitapride [mi]
19. 96623-56-2
20. Cinitapride [mart.]
21. (non-labelled)cinitapride-d5
22. Cinitapride [who-dd]
23. Schembl476454
24. Chembl2104523
25. Schembl19235643
26. Dtxsid60867232
27. Chebi:135642
28. Bcp04096
29. Hy-b2089
30. Akos015909742
31. Bcp9000531
32. Db08810
33. Bcp0726000107
34. Cs-0017505
35. Ft-0665049
36. D07700
37. Q5121012
Molecular Weight | 402.5 g/mol |
---|---|
Molecular Formula | C21H30N4O4 |
XLogP3 | 3.6 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 6 |
Exact Mass | 402.22670545 g/mol |
Monoisotopic Mass | 402.22670545 g/mol |
Topological Polar Surface Area | 113 Ų |
Heavy Atom Count | 29 |
Formal Charge | 0 |
Complexity | 586 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
It is indicated to treat gastrointestinal disorders associated with motility disturbances like gastroesophageal reflux disease (GERD), non-ulcer dyspepsia and delayed gastric emptying.
Anti-Ulcer Agents
Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)
A - Alimentary tract and metabolism
A03 - Drugs for functional gastrointestinal disorders
A03F - Propulsives
A03FA - Propulsives
A03FA08 - Cinitapride
Absorption
The absorption of cinitapride (12mg) following oral administration was rapid, with peak levels being achieved 2 h after dosing; absorption following intramuscular administration (4mg) was even more rapid, with peak levels (50% more that oral levels) being achieved 1 h after dosing.
3-5 h during the first 8 h and a residual half-life greater than 15 h thereafter.
Cinitapride is a substituted benzamide with 5-HT receptor antagonist and agonist activity.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product ...
About the Company : Spansules started in 2000 & now it is one of the leading pellets manufacturing pharmaceutical company with manufacturing facilities and R&D facilities spearheading landmark researc...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Market Place
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?